文献速递乳腺癌

白蛋白结合型紫杉醇改善早期乳腺癌无病生存:GBG 69-GeparSepto研究

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
PubMed 文献 · J Clin Oncol · 2019-05-13

GeparSepto试验将1206例初治乳腺癌患者随机分配接受每周白蛋白结合型紫杉醇或溶剂型紫杉醇,随后表柔比星联合环磷酰胺。中位随访49.6个月,白蛋白结合型紫杉醇组4年侵袭性疾病无生存显著优于溶剂型紫杉醇组(84.0% vs 76.3%,HR 0.66),总生存无显著差异。

要点

  • 白蛋白结合型紫杉醇组4年侵袭性疾病无生存为84.0%,溶剂型紫杉醇组为76.3%(HR 0.66,95%CI 0.51-0.86,P=0.002)。
  • 两组总生存无显著差异(89.7% vs 87.2%,HR 0.82,95%CI 0.59-1.16,P=0.260)。
  • 白蛋白结合型紫杉醇125 mg/m²组周围感觉神经病变缓解中位时间较150 mg/m²组显著缩短。

核心结论

  • 白蛋白结合型紫杉醇较溶剂型紫杉醇显著提高早期乳腺癌患者病理完全缓解率,并转化为显著改善的侵袭性疾病无生存。
  • 白蛋白结合型紫杉醇125 mg/m²组周围感觉神经病变缓解速度较150 mg/m²组显著加快。

研究设计与样本

  • GeparSepto试验为随机对照试验,将组织学确诊的原发性乳腺癌患者按1:1比例随机分配。
  • 患者接受12次每周白蛋白结合型紫杉醇150 mg/m²(研究修正后为125 mg/m²)或每周溶剂型紫杉醇80 mg/m²,两组随后均接受4次表柔比星90 mg/m²联合环磷酰胺600 mg/m²,每3周一次。
  • HER2阳性乳腺癌患者同时接受曲妥珠单抗和帕妥珠单抗双抗体治疗并持续1年。
  • 共1206例患者开始治疗,白蛋白结合型紫杉醇组606例,溶剂型紫杉醇组600例。

主要发现

  • 中位随访49.6个月(范围0.5至64.0个月),共报告243例侵袭性疾病无生存事件(溶剂型紫杉醇组143例,白蛋白结合型紫杉醇组100例)。
  • 4年时,白蛋白结合型紫杉醇组侵袭性疾病无生存为84.0%,溶剂型紫杉醇组为76.3%(HR 0.66,95%CI 0.51-0.86,P=0.002)。
  • 两组总生存无显著差异:白蛋白结合型紫杉醇组89.7% vs 溶剂型紫杉醇组87.2%(HR 0.82,95%CI 0.59-1.16,P=0.260)。
  • 长期随访显示,白蛋白结合型紫杉醇125 mg/m²组周围感觉神经病变缓解中位时间较150 mg/m²组显著缩短。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The GeparSepto trial demonstrated that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic complete remission rate compared with weekly solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatment in patients with primary breast cancer (BC). Here, we report data on long-term outcomes. METHODS: Patients with histologically confirmed primary BC were randomly assigned in a 1:1 ratio to 12 times weekly NAB-paclitaxel 150 mg/m2 (after study amendment, 125 mg/m2) or weekly sb-paclitaxel 80 mg/m2 followed in both arms by four times epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks. Patients with human epidermal growth factor receptor 2 (HER2)-positive BC received dual antibody treatment with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) and pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks) concurrently to chemotherapy and continued for 1 year. RESULTS: A total of 1,206 patients started treatment, 606 with NAB-paclitaxel and 600 with sb-paclitaxel. After a median follow-up of 49.6 months (range, 0.5 to 64.0 months), 243 invasive disease-free survival (iDFS) events were reported (143 in the sb-paclitaxel and 100 in the NAB-paclitaxel arm). At 4 years, overall patients treated with NAB-paclitaxel had a significantly better iDFS compared with sb-paclitaxel (84.0% v 76.3%; hazard ratio, 0.66; 95% CI, 0.51 to 0.86; P = .002), whereas overall survival did not significantly differ between the two treatment arms (89.7% v 87.2%, respectively; hazard ratio, 0.82; 95% CI, 0.59 to 1.16; P = .260). Long-term follow-up of the treatment-related peripheral sensory neuropathy (PSN) showed a significant decrease of the median time to resolve PSN after NAB-paclitaxel 125 mg/m2 compared with NAB-paclitaxel 150 mg/m2. CONCLUSION: The significantly higher pathologic complete response rate with NAB-paclitaxel translated into a significantly improved iDFS in patients with early BC as compared with sb-paclitaxel. PSN improved much faster under NAB-paclitaxel 125 mg/m2 compared with NAB-paclitaxel 150 mg/m2.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Untch M, Jackisch C, Schneeweiss A, et al. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol. 2019. PMID: 31082269. doi:10.1200/JCO.18.01842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。